Cancer cells response on the microtubuler-inhibiting drugs

Abstract

Cancer is one of the age-related diseases with detrimental impact on people survival. Improvement of cancer therapies is a major focus of many scientists around the world. Anticancer drugs based on the microtubules inhibition are successfully used to treat widerange of cancers. Anti-microtubules drugs directly bind to colchicine, vinca and taxol binding sites on beta-tubulin, resulting in the impairment of spindle formation, vesicle transport, cell structure and migration. One of the modes of action anti-tubulin drugs is through causing faults in mitotic spindle function, which lead to the prolonged mitotic block and consequently to cell death. Although, drugs' high toxicity and development of resistance in patients lead to the idea of revisiting the dosage and combination therapies of anti-tubulin drugs, some sources reported that cell migration is more sensitive to microtubule inhibiting drugs than to cell proliferation in endothelial cells. Previously, we reported observations on NIH/3T3 (normal fibroblasts) cell proliferative activity, cell migration and direct test of microtubule dynamics. Thus, we aimed to identify effect of microtubule inhibitors on cancer cell lines. In addition, we compare normal cell lines with human cancer cell lines such as A549 (lung carcinoma), HT1080 (fibrosarcoma) and U118 (glioma).